AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15476525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11493488 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1 MAC (7.4%)
Number of subjects: 8
Study 11493488 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1.5 MAC (10.8%)
Number of subjects: 8
Study 8790024 — intervention group
Group type: EXPERIMENTAL
Intervention: Xemilofiban (5, 10, 15, or 20 mg) administered 8 to 18 hours after abciximab termination
Number of subjects: 74
Study 8790024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ticlopidine) administered 8 to 18 hours after abciximab termination
Number of subjects: 74
Study 1734217 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (12.5 mg/m2/dose) in combination with vincristine, prednisone, and L-asparaginase (VPLI)
Number of subjects: 85
Study 1734217 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (30 mg/m2) in combination with vincristine, prednisone, and L-asparaginase (VPLD)
Number of subjects: 85
Study 1734217 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 85
Study 1734217 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin
Number of subjects: 85
Study 6380903 — intervention group
Group type: EXPERIMENTAL
Intervention: Schering gentamicin 1 mg/kg
Number of subjects: 10
Study 6380903 — intervention group
Group type: COMPARATOR
Intervention: Invenex gentamicin 1 mg/kg
Number of subjects: 10
Study 6380903 — intervention group
Group type: EXPERIMENTAL
Intervention: Schering gentamicin
Number of subjects: 10
Study 6380903 — intervention group
Group type: COMPARATOR
Intervention: Invenex gentamicin
Number of subjects: 10
Study 30171400 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding application (BD)
Number of subjects: 60
Study 30171400 — intervention group
Group type: EXPERIMENTAL
Intervention: Teethmate desensitizer (TM)
Number of subjects: 60
Study 30171400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser application (LS)
Number of subjects: 60
Study 30171400 — intervention group
Group type: COMPARATOR
Intervention: No surface treatment (control, C)
Number of subjects: 60
Study 28504468 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentiated zinc pyrithione (ZPT) antidandruff shampoo
Number of subjects: 24
Study 28504468 — intervention group
Group type: COMPARATOR
Intervention: Placebo cosmetic shampoo
Number of subjects: 24
Study 27015634 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids 2.4 g
Number of subjects: 70
Study 27015634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24958795 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group tutorial
Number of subjects: 114
Study 24958795 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Developmental Teaching (IDT)
Number of subjects: 114
Study 24958795 — intervention group
Group type: COMPARATOR
Intervention: Control group (didactic lecture followed by self-study with online resources)
Number of subjects: 114
Study 24958795 — intervention group
Group type: EXPERIMENTAL
Intervention: IDT and small groups
Number of subjects: 114
Study 24958795 — intervention group
Group type: EXPERIMENTAL
Intervention: IDT group
Number of subjects: 114
Study 22381603 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of intramuscular 17P after tocolysis, repeated semiweekly until 36 weeks or preterm delivery.
Number of subjects: 188
Study 22381603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no 17P treatment).
Number of subjects: 188
Study 22381603 — intervention group
Group type: COMPARATOR
Intervention: 17P treatment and Control group.
Number of subjects: 188
Study 19534374 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% wound infiltration
Number of subjects: 70
Study 19534374 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac incisional infiltration 60mg
Number of subjects: 70
Study 17413559 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular Adsorbents Recirculating System (MARS)
Number of subjects: 8
Study 17413559 — intervention group
Group type: EXPERIMENTAL
Intervention: Prometheus
Number of subjects: 8
Study 17413559 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS
Number of subjects: 8
Study 17413559 — intervention group
Group type: COMPARATOR
Intervention: MARS and Prometheus
Number of subjects: 8
Study 16329019 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 34
Study 16329019 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 34
Study 12134308 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12134308 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative or surgical treatment
Number of subjects: 0
Study 12134308 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials with random assignation
Number of subjects: 0
Study 10457699 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 22
Study 10457699 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated eye)
Number of subjects: 22
Study 7818114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%
Number of subjects: 76
Study 7818114 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 76
Study 2157988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumajecta and Vasolastine (R and V)
Number of subjects: 30
Study 2157988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7021410 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary treatment with isoniazid and PAS for one year in 3 treatment towns
Number of subjects: 1482
Study 7021410 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary treatment with isoniazid alone for one year in 3 treatment towns
Number of subjects: 1482
Study 7021410 — intervention group
Group type: COMPARATOR
Intervention: Control group with no special facilities for diagnosis or treatment
Number of subjects: 1482
Study 30273086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body intervention as an adjunct to SUD treatment
Number of subjects: 217
Study 30273086 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 217
Study 28770298 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA without removal of the lateral posterior femoral cartilage (Group 1)
Number of subjects: 106
Study 28770298 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA with removal of the lateral posterior femoral cartilage (Group 2)
Number of subjects: 106
Study 28770298 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 106
Study 25721879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention, 60-minute sessions, five times a week for 1 year
Number of subjects: 160
Study 25721879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 24685737 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care model applied for 3 months
Number of subjects: 90
Study 24685737 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 90
Study 23051611 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall letter sent to parents of 438 eligible children
Number of subjects: 878
Study 23051611 — intervention group
Group type: COMPARATOR
Intervention: No recall letter sent (control group)
Number of subjects: 878
Study 20027849 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 51
Study 20027849 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration plus resistance training (WBV+RT)
Number of subjects: 51
Study 20027849 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 51
Study 18074914 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and mucosal plication (RAMP)
Number of subjects: 46
Study 18074914 — intervention group
Group type: COMPARATOR
Intervention: Ligature and excision procedure (LEP)
Number of subjects: 46
Study 15363817 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (median 3 years)
Number of subjects: 96
Study 15363817 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment levels in patients with hypertension
Number of subjects: 96
Study 15363817 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP‐9 levels
Number of subjects: 96
Study 11481349 — intervention group
Group type: EXPERIMENTAL
Intervention: marimastat 5 mg bid
Number of subjects: 414
Study 11481349 — intervention group
Group type: EXPERIMENTAL
Intervention: marimastat 10 mg bid
Number of subjects: 414
Study 11481349 — intervention group
Group type: EXPERIMENTAL
Intervention: marimastat 25 mg bid
Number of subjects: 414
Study 11481349 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine 1,000 mg/m2
Number of subjects: 414
Study 9669426 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (a xanthine oxidase inhibitor)
Number of subjects: 39
Study 9669426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7923306 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 440 mg
Number of subjects: 226
Study 7923306 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 226
Study 7923306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 3074621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 908
Study 3074621 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 908
Study 3074621 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencyclan
Number of subjects: 908
Study 3074621 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller doses of medications
Number of subjects: 908
Study 3074621 — intervention group
Group type: COMPARATOR
Intervention: Placebo or other medication
Number of subjects: 908
Study 29124630 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 16
Study 29124630 — intervention group
Group type: COMPARATOR
Intervention: Placebo Inspiratory Muscle Training (P-IMT)
Number of subjects: 16
Study 28361654 — intervention group
Group type: EXPERIMENTAL
Intervention: Active play intervention with staff training and 60-minute weekly sessions for 6 weeks
Number of subjects: 162
Study 28361654 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only a resource pack
Number of subjects: 162
Study 25475110 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg alternate-day aspirin
Number of subjects: 27939
Study 25475110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27939
Study 22033049 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based education (4 hours of training)
Number of subjects: 60
Study 22033049 — intervention group
Group type: COMPARATOR
Intervention: Traditionally trained (control group)
Number of subjects: 60
Study 20167179 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 29
Study 20167179 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 29
Study 17964789 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole plus antiepileptic drugs (group A)
Number of subjects: 300
Study 17964789 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptic drugs alone (group B)
Number of subjects: 300
Study 15475605 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects seated
Number of subjects: 10
Study 15475605 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects supine
Number of subjects: 10
Study 15475605 — intervention group
Group type: COMPARATOR
Intervention: Control subjects supine
Number of subjects: 10
Study 15475605 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects seated and supine
Number of subjects: 10
Study 15475605 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 10
Study 12036523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyridamole (75 mg twice a day for 5 days)
Number of subjects: 20
Study 12036523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10219433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal massage of the 'yingxiang' acupuncture point for 30 seconds
Number of subjects: 20
Study 10219433 — intervention group
Group type: COMPARATOR
Intervention: Control group without nasal massage
Number of subjects: 20
Study 7609566 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and protamine dosing according to in vitro predictive tests integrating drugs, tests, and patient response
Number of subjects: 46
Study 7609566 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of heparin and protamine dosing
Number of subjects: 46
Study 2505717 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 34
Study 24829 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study 24829 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids combined with an adrenergic beta-stimulant
Number of subjects: 0
Study 31246607 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal adductor canal block
Number of subjects: 108
Study 31246607 — intervention group
Group type: COMPARATOR
Intervention: Mid adductor canal block
Number of subjects: 108
Study 31246607 — intervention group
Group type: COMPARATOR
Intervention: Distal adductor canal block
Number of subjects: 108
Study 29882510 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (TMPP tablet, 200 mg)
Number of subjects: 20
Study 29882510 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (TMPP tablet, 200 mg)
Number of subjects: 20
Study 27129086 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 84
Study 27129086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 84
Study 27129086 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 84
Study 27129086 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 84
Study 25223986 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastases-directed therapy (MDT) followed by active surveillance
Number of subjects: 0
Study 25223986 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance only
Number of subjects: 0
Study 23032234 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric chips
Number of subjects: 0
Study 23032234 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin chips
Number of subjects: 0
Study 23032234 — intervention group
Group type: COMPARATOR
Intervention: Traditional nonsurgical methods
Number of subjects: 0
Study 20222769 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (CIMT)
Number of subjects: 32
Study 18585495 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (5 mg/kg per day) for 60 days
Number of subjects: 3000
Study 18585495 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 3000
Study 16126045 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis (twice weekly for up to 6 weeks)
Number of subjects: 81
Study 16126045 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole prophylaxis (previous dosing schedule)
Number of subjects: 81
Study 12823779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐Chlorodeoxyadenosine (2‐CdA), administered as a single 7‐day course
Number of subjects: 0
Study 12823779 — intervention group
Group type: EXPERIMENTAL
Intervention: BL22, a fusion of an anti‐CD22 antibody linked to a portion of the Pseudomonas exotoxin A
Number of subjects: 0
Study 12823779 — intervention group
Group type: COMPARATOR
Intervention: 2‐deoxycoformycin
Number of subjects: 0
Study 10193737 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg every other day)
Number of subjects: 14916
Study 10193737 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibrinogen levels (>=343 mg/dl)
Number of subjects: 14916
Study 10193737 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 14916
Study 8616992 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 20
Study 8616992 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study 2114029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Rifampicin, Isoniazid, and Pyrazinamide (administered separately or in combined preparations)
Number of subjects: 250
Study 395310 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation procedure
Number of subjects: 40
Study 395310 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional biofeedback
Number of subjects: 40
Study 395310 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional biofeedback plus criterion information
Number of subjects: 40
Study 395310 — intervention group
Group type: COMPARATOR
Intervention: Control group (visual feedback display with no instructions)
Number of subjects: 40
Study 30260676 — intervention group
Group type: EXPERIMENTAL
Intervention: Total etching (TE)
Number of subjects: 20
Study 30260676 — intervention group
Group type: COMPARATOR
Intervention: Partial etching (PE)
Number of subjects: 20
Study 27229727 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without F, CaGP or TMP)
Number of subjects: 12
Study 27229727 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 ppm F (550F)
Number of subjects: 12
Study 27229727 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 ppm F (1100F)
Number of subjects: 12
Study 27229727 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 ppm F with 1% TMP (550F-TMP)
Number of subjects: 12
Study 27229727 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 ppm F with 0.25% CaGP (550F-CaGP)
Number of subjects: 12
Study 26376464 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 44
Study 26376464 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (4 mg)
Number of subjects: 44
Study 26376464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 44
Study 23819814 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele and CT+TT genotypes of rs3918242
Number of subjects: 258
Study 23819814 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum levels of MMP‐9
Number of subjects: 258
Study 23819814 — intervention group
Group type: EXPERIMENTAL
Intervention: T alleles in the CAD group
Number of subjects: 258
Study 23819814 — intervention group
Group type: COMPARATOR
Intervention: Variant genotypes of rs17576
Number of subjects: 258
Study 21430255 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g sunflower oil (rich in n-6 PUFA)
Number of subjects: 13
Study 21430255 — intervention group
Group type: COMPARATOR
Intervention: 50 g butter (rich in SFA)
Number of subjects: 13
Study 21499649 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (0.12%)
Number of subjects: 60
Study 21499649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (0.5%)
Number of subjects: 60
Study 21499649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium iodine (2%)
Number of subjects: 60
Study 21499649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mouthwash or initial dental treatment)
Number of subjects: 60
Study 17909953 — intervention group
Group type: EXPERIMENTAL
Intervention: Flebogamma 5% DIF administered at a dose of 300‐600 mg/kg every 21‐28 days for 12 months
Number of subjects: 46
Study 17909953 — intervention group
Group type: EXPERIMENTAL
Intervention: Flebogamma 5% DIF
Number of subjects: 46
Study 16341485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free hernioplasty
Number of subjects: 106
Study 16341485 — intervention group
Group type: COMPARATOR
Intervention: Conventional hernioplasty
Number of subjects: 106
Study 11934542 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-energy diet therapy for 4 weeks
Number of subjects: 103
Study 11934542 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight subjects (BMI 18.5 < or = BMI < 25.0)
Number of subjects: 103
Study 11934542 — intervention group
Group type: COMPARATOR
Intervention: Underweight subjects (BMI < 18.5)
Number of subjects: 103
Study 11934542 — intervention group
Group type: COMPARATOR
Intervention: Overweight (25 < or = BMI < 30) and obese subjects (30 < or = BMI < 40, and BMI > or = 40)
Number of subjects: 103
Study 11934542 — intervention group
Group type: COMPARATOR
Intervention: Menstrual cycle
Number of subjects: 103
Study 10747518 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 degrees C
Number of subjects: 0
Study 10747518 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 degrees C
Number of subjects: 0
Study 10747518 — intervention group
Group type: COMPARATOR
Intervention: Non-cooled group (28 degrees C)
Number of subjects: 0
Study 10747518 — intervention group
Group type: COMPARATOR
Intervention: Cooled group (20 degrees C)
Number of subjects: 0
Study 8747844 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle sympathetic nerve activity (MSNA) in patients with ALS
Number of subjects: 12
Study 8747844 — intervention group
Group type: COMPARATOR
Intervention: Muscle sympathetic nerve activity (MSNA) in controls
Number of subjects: 12
Study 8747844 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilting effect on MSNA and blood pressure in ALS patients
Number of subjects: 12
Study 8747844 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MSNA with disability score and other factors in ALS patients
Number of subjects: 12
Study 8747844 — intervention group
Group type: EXPERIMENTAL
Intervention: MSNA at rest in ALS patients
Number of subjects: 12
Study 2478368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug therapy (choline-piracetam)
Number of subjects: 0
Study 795157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibasole and ascorbic acid
Number of subjects: 0
Study 795157 — intervention group
Group type: COMPARATOR
Intervention: Glucose (Control)
Number of subjects: 0
Study 31210019 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg subconjunctival injection of triamcinolone acetonide (TA)
Number of subjects: 101
Study 31210019 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/ml dexamethasone eye drops (DEX)
Number of subjects: 101
Study 31210019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TA and DEX)
Number of subjects: 101